Obinutuzumab 1g/40ml solution for infusion vials

BackgroundLupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), often leading to end-stage renal disease. Despite current immunosuppressive therapies, complete renal remission remains limited. Obinutuzumab, a type II anti-CD20 monoclonal antibody, offers enhanced B-cell depletion compared to type I antibodies and may improve renal outcomes in LN. This systematic review evaluates the efficacy and safety of obinutuzumab in treating adult patients with proliferative LN.MethodsThis review was registered with PROSPERO (CRD420251074418) and conducted in accordance with the PRISMA guidelines. A comprehensive search of PubMed, Cochrane, Embase, Scopus, and clinical trial registries was conducted through June 2025. Eligible studies were randomized controlled trials (RCTs) comparing obinutuzumab vs. placebo in adult patients with biopsy-confirmed active LN. Primary outcomes included complete renal response (CRR), proteinuria, and estimated glomerular filtration rate (eGFR). Secondary outcomes included immunological markers and adverse events. Data were synthesized qualitatively due to the limited available trials.ResultsTwo RCTs (REGENCY 2025 and NOBILITY 2022) with 396 patients met the inclusion criteria. Obinutuzumab significantly improved CRR (46.4% in REGENCY at week 76; 41% in NOBILITY at week 104) and reduced proteinuria (UPCR ConclusionObinutuzumab appears to be a promising therapy for proliferative LN, offering enhanced renal response and immunological benefits. Its potential for long-term renal protection and steroid-sparing effects supports further investigation through large-scale comparative trials.

Abstract licence: CC BY

Background: The benefit of specific B cell-targeted therapy in primary membranous nephropathy has been consistently demonstrated and is part of guideline-directed therapy. Though effective, Rituximab displays a highly variable response rate possibly owing to incomplete peripheral B cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody which offers greater sustained peripheral B cell depletion and thus may result in improved clinical effect. This meta-analysis compares clinical efficacy of Obinutuzumab with Rituximab for the treatment of primary membranous nephropathy. Methods: A comprehensive search of PubMed, EMBASE, and Google Scholar was conducted on 10 October 2025. The search identified all studies which directly compared results of Obinutuzumab with Rituximab in the treatment of primary membranous nephropathy. Risk of bias was assessed using the Cochrane ROBINS-I tool. Data extraction and statistical analysis were performed using RevMan 5.1 software, assessing heterogeneity with the I2 statistic. Results: Ultimately, three retrospective studies including a total of 161 participants were analyzed. The pooled estimated odds ratio for total clinical remission at 6 months was 2.84 (95% CI [1.42-5.69], p = 0.003, I2 = 0%), and at 12 months was 12.25 ([95% CI 2.67-56.28]), p = 0.001, I2 = 0%). The pooled estimated odds ratio for complete clinical remission at 6 months was 1.78 (95% CI [0.25-12.63], p = 0.57, I2 = 0%) at 12 months was 4.12 (95% CI [1.36-12.48], p = 0.01, I2 = 0%). The pooled estimated odds ratio for immunologic remission at 6 months was 6.18 (95% CI [1.57-24.39], p = 0.009, I2 = 58%), and at 12 months was 5.56 (95% CI [1.50-20.64], p = 0.01, I2 = 0%). The pooled estimated odds ratio for peripheral B cell depletion at 6 months was 3.91 (95% CI [0.99-15.40], p = 0.05, I2 = 25%). Discussion: Obinutuzumab signals improvement in clinically relevant end points when compared with Rituximab for the treatment of primary membranous nephropathy but will require confirmation with head-to-head prospective data. The main limitations of this study include small sample sizes, geographic restriction, and retrospective design of the studies resulting in reduced generalizability. Other: There was no funding for this study. This review has been registered with PROSPERO (ID 1218735).

Abstract licence: CC BY

AbstractFollicular lymphoma with progression of disease within 24 months (POD24) is associated with poor prognosis and represents clinical challenges. Therefore, we performed a systematic review and pooled analysis of patients with POD24. Twenty-one trials involving 1242 participants were included, assessing the overall response rate (ORR), complete response (CR), duration of response, and progression-free survival. In some trials, we compared pooled response rates between POD24 and non-POD24 populations with the same treatment regimen. Four trials evaluated chimeric antigen receptor (CAR) T-cell therapy in patients with POD24. Pooled analysis showed an ORR of 91.2% (95% confidence interval [CI], 83.7-98.7) with significant heterogeneity (P = .0414; I2 = 68.61%) and a CR of 75.7% (95% CI, 55.1-96.4) with significant heterogeneity (P< .0001; I2 = 93.99%). The specific response rates for different bispecific antibodies in POD24 were pooled analysis, the ORR was 81.6% (95% CI, 75.9-87.3) with no heterogeneity (P = .6958; I2 = 0%), and the CR was 65.7% (95% CI, 57.1-74.3) with moderate heterogeneity (P = .2148; I2 = 34.99%). For anti-CD19 antibody-drug conjugates (ADCs)/monoclonal antibodies (mAbs), the ORR and CR rate for loncastuximab plus rituximab and tafasitamab plus R2 (lenalidomide + rituximab) were 100% and 79.3%, and 87.5% and 43.2%, respectively. Phosphatidylinositol 3-kinase inhibitors and anti-CD20 mAb-containing regimens were also analyzed in pooled analyses. Our results demonstrated that anti-CD19 CAR T-cell therapy achieved the highest CR rate. Additionally, bispecific antibodies, anti-CD19 ADCs/mAbs, and the combination of lenalidomide with obinutuzumab or rituximab also exhibited excellent efficacy. Notably, lenalidomide plus obinutuzumab showed superior efficacy compared with R2.

Abstract licence: CC BY-NC-ND

BackgroundRefractory membranous nephropathy (MN) remains challenging. We aim to compare the efficacy and safety of obinutuzumab versus rituximab in adults with refractory or relapsing MN, using a retrospective, single-center study design.MethodsThis retrospective, single-center cohort study was conducted at the Fifth Affiliated Hospital of Wenzhou Medical University from January 2022 to January 2025. Eleven patients received obinutuzumab, and twenty-two matched controls received rituximab after propensity score matching (1:2). Inclusion criteria were biopsy-confirmed primary MN, age between 18 and 80 years, and a diagnosis of refractory disease. The primary endpoints were a composite measure of treatment response (including partial remission [PR] and complete remission [CR]); secondary endpoints included immunological remission and safety. Kaplan-Meier analyses were used to estimate time to response and time to CR; log-rank tests compared groups. Multivariate Cox regression identified factors associated with response.ResultsBaseline characteristics were balanced. Obinutuzumab achieved higher overall response and CR rates (log-rank p = 0.0074 and p = 0.012, respectively). At 18 months, CR was 54.6% with obinutuzumab versus 9.1% with rituximab (p = 0.024). Obinutuzumab induced prolonged B cell depletion and faster attainment of immunological remission (anti-PLA2R ConclusionsIn this preliminary retrospective analysis, obinutuzumab was associated with higher response rates than rituximab in refractory membranous nephropathy, with comparable safety.Nevertheless, given the small sample size and retrospective design, these findings should be interpreted as hypothesis-generating. Prospective randomized controlled trials are required to confirm these observations.

Abstract licence: CC BY-NC-ND

Background: Pirtobrutinib has recently emerged as a promising first-line treatment option for chronic lymphocytic leukemia (CLL). Unlike currently established regimens, which are generally based on doublet combinations, pirtobrutinib can be administered as monotherapy. Because no head-to-head trials comparing pirtobrutinib with contemporary first-line combinations are currently available, indirect comparative evidence may help define its potential role. Methods: A non-anchored indirect comparison based on reconstructed individual patient data (IPD) was conducted using published Kaplan-Meier curves from randomized controlled trials evaluating first-line treatments for CLL. Progression-free survival (PFS) was the endpoint of interest. Reconstructed IPD were generated using WebPlotDigitizer and the IPDfromKM algorithm. Pirtobrutinib monotherapy was compared indirectly with acalabrutinib plus obinutuzumab, venetoclax plus obinutuzumab, and venetoclax plus ibrutinib. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using univariate Cox models. Results: The analysis included four randomized trials. Compared with pirtobrutinib monotherapy, HRs for PFS were 0.5544 (95%CI, 0.2696-1.1397) versus venetoclax plus obinutuzumab, 0.4583 (95%CI, 0.2066-1.0200) versus venetoclax plus ibrutinib, and 1.4453 (95%CI, 0.6684-3.1240) versus acalabrutinib plus obinutuzumab. Confidence intervals were wide and crossed unity in all comparisons, indicating substantial statistical uncertainty. Visual inspection of reconstructed Kaplan-Meier curves did not suggest inferior PFS for pirtobrutinib relative to established doublet regimens. Conclusions: This exploratory non-anchored analysis suggests that pirtobrutinib monotherapy may provide PFS outcomes broadly comparable to current first-line combination regimens for CLL. Given the methodological limitations inherent to indirect comparisons, prospective head-to-head studies are needed to clarify the optimal positioning of pirtobrutinib in treatment-naïve CLL.

Abstract licence: CC BY